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Proton minibeam radiation
therapy is a novel imple-
mentation of spatial frac-
tionation for normal tissue
sparing that maintains tumor
control by way of a homo-
geneous tumor dose using
beam widening in tissue. The
side effects of minibeam and
homogeneous irradiation
were compared in the ears of
BALB/c mice at the same
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http://dx.doi.org/10.1016/j.ijrobp.2015.10.020Purpose: Proton minibeam radiation therapy is a novel approach to minimize normal
tissue damage in the entrance channel by spatial fractionation while keeping tumor
control through a homogeneous tumor dose using beam widening with an increasing
track length. In the present study, the dose distributions for homogeneous broad beam
and minibeam irradiation sessions were simulated. Also, in an animal study, acute
normal tissue side effects of proton minibeam irradiation were compared with homo-
geneous irradiation in a tumor-free mouse ear model to account for the complex
effects on the immune system and vasculature in an in vivo normal tissue model.
Methods and Materials: At the ion microprobe SNAKE, 20-MeV protons were
administered to the central part (7.2  7.2 mm2) of the ear of BALB/c mice, using
either a homogeneous field with a dose of 60 Gy or 16 minibeams with a nominal
6000 Gy (4  4 minibeams, size 0.18  0.18 mm2, with a distance of 1.8 mm).
The same average dose was used over the irradiated area.
Results: No ear swelling or other skin reactions were observed at any point after mini-
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Conclusions: These results show that proton minibeam radiation therapy results in
reduced adverse effects compared with conventional homogeneous broad-beam irradia-
tion and, therefore,might have the potential to decrease the incidence of side effects result-
ing from clinical proton and/or heavy ion therapy.  2016 The Authors. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Worldwide, approximately 50% of all patients with cancer
undergo radiation therapy (1, 2). However, despite tech-
nical improvements, the success of radiation therapy is still
hampered by the severe side effects that develop in normal
tissue. Radiation therapy with protons or heavy ions offers
an important advantage compared with photons with
respect to the dose distribution in the depth of the tissue.
This allows a sharp decrease in the dose directly behind the
tumor (3). However, proton and heavy ion irradiation also
causes normal tissue damage and can induce the develop-
ment of secondary cancer, with detrimental effects on the
patient’s well-being after radiation therapy. New technol-
ogies such as microbeam radiation therapy (MRT), which
was developed at Brookhaven National Laboratory (4) and
the European Synchrotron Radiation Facility (5-8), and
proton microchannel radiation therapy, developed at the ion
microprobe SNAKE (Superconducting Nanoprobe for
Applied nuclear [Kern] physics Experiments) in Munichs for homogeneous broad
depth of 7 to 9.5 cm under
aussian pencil beams wit
irradiation uses Gaussian p
ith an interbeam distance
with a factor of about 10-20
etween. The dose distribut
ose algorithm (12) using M
experiment, leading to gr(9), have provided implementations of spatial fractionation,
with the aim of reducing normal tissue damage in the
entrance channel. However, these 2 methods have shown
differences in the irradiation of the tumor. X-ray MRT leads
to an inhomogeneous dose distribution through the pre-
served microarray geometry. In contrast, proton microbeam
or minibeam radiation therapy results in a homogeneous
dose distribution in the tumor, similar to conventional broad
beam irradiation (9, 10). The initially micrometer-size, or at
least submillimeter, proton beams spread with increasing
track length owing to interactions with the traversed tissue
or their initial divergence, resulting in a homogeneous dose
distribution within the tumor tissue when the minibeam
distances have been adjusted accordingly (Fig. 1).
First experimental evidencewith protonmicrobeams in an
in vitro 3-dimensional human skin model demonstrated
reduced negative irradiation effects of microchannel irradia-
tion compared with a homogeneous broad beam irradiation
(9). In that comparative in vitro study, greater cell viability
and lower genetic damage was demonstrated using the MTTtarget
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mide) tissue viability and micronuclei assays, with a reduced
and shorter inflammatory response,measured as the release of
inflammatory cytokines in the culture medium of the skin (9).
For future therapeutic applications of this method, larger
beam sizes and thus larger interbeam distances might be
favored owing to the greater feasibility of creating “proton
minibeams” with a full width at half maximum (FWHM) in
the range of 0.1 to 1 mm rather than microbeams, for as
long as a homogeneous irradiation of deep lying tumors is
obtained from the laterally spreading proton beams. The
proton beams spread laterally with increasing depth in tis-
sue due to multiple coulomb scattering, leading to a ho-
mogeneous dose distribution in a deep lying tumor if the
beam distances are chosen appropriately. Studies using
larger beam sizes and interbeam distances have shown
similar reduced side effects in an artificial in vivo model
(13, 14). However, clinically relevant proof-of-concept
results can only be obtained using proton minibeam irra-
diation in an animal model in which the complexity of
irradiation effects, including the response of the vasculature
and immune system, can be analyzed.
In the present experiments, the acute side effects of
proton minibeam irradiation were compared with those of
conventional homogeneous proton irradiation of normal
tissue in a validated mouse model. In this mouse model, the
effects of minibeam irradiation to mouse ears were
compared with those of homogeneous irradiation. The
irradiation geometry was determined in a simulation for a
human patient, such that it would fit the irradiation of a
target volume at a depth of 7 to 9.5 cm from 1 direction.
However, owing to the limited beam energy and mouse
thickness, tumor irradiation was not a part of the present
study. Regardless, the tumor control should not change
between the homogeneous and minibeam applications,
because in both cases, the dose distributions and, thus, the
treatment conditions would be the same for the minibeam
and normal proton therapy (Fig. 1).
The mean proton dose of 60 Gy applied in a single
fraction was chosen because of the results from a pilot x-
ray irradiation experiment using varying homogeneous
doses in mouse ears. That pilot experiment showed serious
inflammatory reactions at the 60-Gy dose. It should be
noted that the minibeam shape was square instead of
Gaussian in the experiment, which led to slightly higher
maximum doses (in the skin) than in the simulation. The
outcomes of these proof-of-concept studies provide the first
basis for a future application of this novel radiation
therapeutic approach in humans.Methods and Materials
Animal model and ethical approval
The 10- to 12-week-old female BALB/c mice (Charles River
Laboratories, Sulzfeld, Germany) were kept in a temperature-regulated animal facility exposed to a 12-hour light/dark
cycle, with ad libitum access to food and water. The District
Government of Upper Bavaria approved all animal experi-
ments, which were performed in accordance with the animal
welfare and ethical guidelines of our institutions.
BALB/c mice were used for the irradiation experiments
of the ears because of their lack of pigmentation, the
presence of only a few thin hairs on the ears, the relatively
large size of approximately 1 cm in diameter and thickness
of approximately 250 mm. These factors ensured a precise
dose application and allowed for the detection of 20-MeV
protons (range in water w4.6 mm) in transmission.
Simulations
The dose distributions for homogeneous broad beam
(Fig. 1a) and minibeam (Fig. 1b) irradiation of a model
target volume with a size of 2.5  1.5  1.5 cm3 in a depth
of 7 to 9.5 cm underneath the surface of a patient from
1 direction were simulated. The dose distributions were
calculated using an open-source planning system compu-
tational environment for radiotherapy research and an
additional proton dose algorithm using Monte Carlo-
generated pencil beams. Figure 1a shows a possible con-
ventional treatment plan using Gaussian pencil beams with
an FWHM of w4.2 mm in a matrix and a distance of
1.8 mm, leading to a homogenous dose distribution in the
target and the skin. For the minibeam irradiation (Fig. 1b),
the pencil beam size was reduced to an FWHM of 0.18 mm,
keeping the same matrix irradiation geometry. Tissue
sparing was optimized using a maximized interbeam dis-
tance of proton minibeams under the constraint of obtaining
a homogeneous dose distribution within the tumor (ie,
within 95% to 107% of the prescribed dose; Fig. 1). The
irradiation techniques used the same total number of pro-
tons, leading to the same average target dose but different
dose distributions in the healthy tissue in front of the target.
Irradiation conditions for the proton study
The beam dimensions and distances chosen for the study of
normal tissue reactions to proton therapy corresponded to
those required to treat a tumor with a homogeneous dose
distribution lying at a depth of 7 cm below the skin, as
described in the previous section. To investigate the acute
side effects of minibeam radiation therapy in healthy tissue,
a small animal model was chosen, without a tumor. The
right ears of BALB/c mice were irradiated using a matrix
with an interbeam distance of 1.8 mm, a square size of
0.18  0.18 mm2, and nominal dose of 6000 Gy (Fig. 2;
beam preparation provided in Appendix E1; available on-
line at www.redjournal.org). This resulted in a mean dose
across the irradiated area of 60 Gy. For comparison, a
homogeneous proton irradiation at the same mean skin dose
of 60 Gy was used and included the same number of pro-
tons in an irradiation field of 7.2  7.2 mm2 (collimated
2mmHFMB
BA
Fig. 2. Irradiation geometry of the mouse ear study.
Photograph of Gafchromic film behind mouse ear imme-
diately after irradiation with minibeams (MB)
(0.18  0.18 mm2) (A) and homogeneous field (HF) (B).
Owing to the limited sensitivity range of the films, no ab-
solute values of the irradiated high doses could be extracted
from the images. Minibeam dimensions are enlarged due to
beam widening in the ear.
Table 1 Skin reaction scoring
Skin score Description
Score A (erythema)
0 No erythema
0.5 Mild erythema
1.5 Definite erythema
3 Severe erythema
Score B (desquamation)
0 No
1 Dry desquamation
2 Crust
3 Moist desquamation
Data modified from Law et al (18).
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www.redjournal.org).
Thus, a matrix with the same interbeam distance of
1.8 mm was used in the animal experiment and our simu-
lation (Fig. 1a). However, for ease of preparation, we used
squares instead of Gaussian minibeams in the animal
experiment. The mean skin dose of 60 Gy was determined
in a pilot study with X rays to obtain strong reactions from
the irradiation of the mouse ears in the homogenous cases
(Appendix E1; available online at www.redjournal.org).
The single fraction dose required to obtain similar normal
tissue reactions would be lower in humans.
For a 90-day follow-up study, 12 BALB/c mice were
irradiated with minibeams, 12 with a homogeneous field,
and 10 with sham irradiation. The latter group served as the
control group. Another 18 mice similarly underwent irra-
diation for histologic analysis at 15, 25, and 36 days after
irradiation (3 mice per irradiation group [minibeam and
homogeneous field] and measurement point).
Irradiation using 20-MeV protons was performed at the
ion microprobe SNAKE, which has been adapted for bio-
logic experiments using cells, tissues, and animals (15-17).
A specially developed, temperature-controlled aluminum
holder allowed for the irradiation of the central part of the
right ear, with the rear of the ear facing the beam. With
every proton traversing the ear (range w4.6 mm much
greater than ear thickness) and reaching a scintillator-pho-
tomultiplier detector positioned approximately 5 cm behind
the ear, the dose could be calculated from the number of
protons applied to a specific area on the skin and the linear
energy transfer value (2.66 keV/mm at the ear). However,
because of the required high particle count rates in the MHz
range (to ensure irradiation times of <30 minutes and
anesthesia time of <45 minutes), the dead time of the
detector and the detection electronics (w15%-35%,
depending on irradiation mode) had to be corrected using
dosimetry with radiochromic films.Irradiation was performed with the mice under general
anesthesia, which was induced by intraperitoneal injection
of medetomidine (0.5 mg/kg), midazolam (0.5 mg/kg), and
fentanyl (0.05 mg/kg). The antagonist atipamezole (2.5 mg/
kg), flumazenil (0.5 mg/kg), and naloxone (1.2 mg/kg) was
administered subcutaneously that maximum 45 min after
induction, the antagonist was administered.
Ear thickness measurements
During a 90-day follow-up period, the thickness of the treated
right ear and the untreated left ear was measured regularly in
triplicate using a specially adapted electronic external
measuring gauge (C1X079; Kro¨plin GmbH, Schlu¨chtern,
Germany), with measuring contacts 6 mm in diameter.
Skin reaction scoring
Acute skin reactions resulting after irradiationweremonitored
with regard to erythema, desquamation, changes in ear
morphology, and hair loss. Hair loss was surveyed as an
additional skin reaction in the mouse model. However, it was
not added to the skin score of the inflammatory response.
Therefore, this score only consisted of the 2 parts, erythema
(score A) and desquamation (score B), which were simply
summed togive a total skin score (Table 1,modified from[18]).
Histologic findings
The mice were euthanized at 15, 25, 36, and 90 days after
irradiation, and the ears were dissected, fixed in formalin,
and embedded in paraffin. Tissue sections were cut (3-mm
thickness) and stained with hematoxylin and eosin for
microscopic examination.
Results
Dose distributions for proton minibeams and
homogeneous field irradiation
The homogeneous and minibeam irradiation modes are
shown in Figure 2, using radiochromic film mounted
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Fig. 3. Ear thickness (A), swelling (B), and skin reactions (C) after proton irradiation with minibeams (MB) and homo-
geneous field (HF) compared with x-ray irradiation. Ear swelling was determined as the difference in ear thickness between
the irradiated (right) and unirradiated (left) ears and was only displayed for comparison of minibeam irradiation with low x-
ray doses. The skin score is the sum of the erythema and desquamation score (Table 1). Abbreviation: COZ control group.
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are identifiable owing to the saturation effects). Quantita-
tive characterization of the irradiation fields in the 2 modes
was also done with radiochromic films (Gafchromic EBT3
[19]) mounted at the mouse ear position (without the mouse
ear). The number of applied protons had to be downscaled
to fit the sensitivity range of the film. The mean doses of the
2 irradiation modes were in good agreement with the pre-
scribed dose of 60 Gy: mean 59  5 Gy for the minibeam
irradiation mode and 58  6 Gy for the homogeneous
mode. The dose uncertainty mainly resulted from the
radiochromic film dosimetry to correct for the detector dead
times at the required high count rates and the uncertainty of
the field sizes.
Ear swelling
The ears irradiated with minibeams showed no increase in
ear thickness at any time after irradiation within the mea-
surement accuracy of about 10% to 15% (Fig. 3a; Fig. E3;
available online at www.redjournal.org). In contrast,
homogeneous irradiation led to significant ear swelling of
4 times the initial thickness (ie, >1 mm). The maximumof the average thickness was reached approximately
4 weeks (days 25-26) after irradiation; however, the indi-
vidual curves differed in shape and peak among the 12
homogeneously irradiated mice. A comparison with the
x-ray curves showed a very similar response for the ears
irradiated homogeneously with 60 Gy with respect to the
maximal thickness and time required for development. To
determine the x-ray dose yielding an equivalent response to
that of the minibeams, the ear swelling (ie, the difference
between the right [irradiated] and left [unirradiated] ear;
mean thickness of all measurements [left ear]) was deter-
mined to account for the different initial ear thicknesses
between the proton and x-ray groups (Fig. 3b). Ear swelling
after homogeneous x-ray irradiation with 10 Gy (P<.01)
and 20 Gy (P<.001) was significantly greater than that of
the minibeam irradiated mice from days 20 to 74 after
irradiation. Irradiation with 2- and 5-Gy X rays did not
produce significant swelling relative to the sham-irradiated
controls or relative to the minibeam irradiation group
(P>.5). In summary, these data indicate that minibeam
irradiation with a mean dose of 60 Gy induces less ear
swelling than homogeneous x-ray irradiation at 10 Gy
(Table 2).
Table 2 Summary of results for all endpoints
Endpoint Homogeneous field Minibeams
Minibeam equivalent
x-ray dose (Gy)
Ear swelling Up to fourfold No <10
Erythema Severe No <20
Desquamation Crust and moistness No <40
Changes in ear morphology Waviness, bending, stiffness No <40
Hair loss In irradiation field No <40
Histologic findings Loss of sebaceous glands, inflammation,
fibrosis, enlargement of epidermis
No changes visible NA
Abbreviation: NA Z not applicable.
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Erythema, desquamation, and other skin reactions such as
hair loss were monitored at the same regular intervals as the
monitoring of the ear thickness. Because the temporal
development was very similar for erythema and desqua-
mation, both scores (Table 1) were summed to obtain a
single score for the acute inflammatory response after
irradiation (Fig. 3c). For the homogeneously irradiated ears,
mild skin reddening occurred first around day 9 after irra-
diation, and dry desquamation began about 17 days after
radiation therapy. The maximum skin score, in the presence
of definite to severe erythema, crust formation, and even
partial moist desquamation, was reached more or less
simultaneously with the date of maximum ear swelling,
about 25 days after irradiation. These symptoms returned to
normal levels from about day 46 onward. A comparison
with the x-ray data displayed very similar behavior for ears
irradiated homogeneously with 60-Gy protons and X rays.
Furthermore, changes in the ear morphology, such as
waviness, bending, and stiffness, were detected in several
of the homogeneously irradiated ears. A loss of hair in the
irradiated field first became visible at the decline of
desquamation about 4 to 5 weeks after irradiation.
However, no visible skin reaction or hair loss was detected
at any measurement point after proton minibeam irradiation,
identifiable by the constant skin score of 0 in Figure 3c.
This corresponded to the response of the ears irradiated with
x-ray doses of 10 Gy, and 20 Gy resulted in a measurable
increase in the skin score (mainly mild erythema).Histologic findings
Representative examples of the histologic sections of the
mouse ears are shown in Figure 4. No noticeable changes
were found in any skin samples of the minibeam-irradiated
mouse ears at all analyzed measurement points. Because it is
almost impossible to ensure a cut directly through 1 of the
minibeams, it could not be excluded that changes had
occurred directly in the irradiated spots. However, most of
the skin area after microbeam irradiation was unchanged.
The histologic findings of samples taken 15 days to 3 monthsafter homogenous irradiation differed significantly from
their corresponding controls. From day 15 onward, the
sebaceous glands were missing in the irradiated field but
not in the surrounding skin and did not recover until day 90.
At the time of the highest skin score around day 25,
significant swelling of the epidermis was found in both skin
layers, accompanied by inflammation and fibrosis. The
decrease in the measured ear thickness at day 36 correlated
well with a decrease in the swelling of the epidermis and a
decline in the fibrotic area, as displayed in the histologic
sections. No change in the abundance and appearance of the
hair follicles was detected in the homogeneously irradiated
ears at any point; however, the hair growth was still impeded
4 to 5 weeks after irradiation until the end of the observation
period.Discussion
In radiation therapy, the occurrence of normal tissue injury
often limits the radiation dose that can be maximally
applied to the tumor. Despite advanced treatment tech-
niques with highly conformal treatment planning, skin re-
actions still occur in the irradiated region (20). The acute
radiation effects of the skin often start as modest erythema
and continue, becoming dry or confluent moist desquama-
tion and leading to discomfort and pain (20). Necrosis and
edema usually occur within 2 weeks after irradiation and
result from cell death of keratinocytes in the epidermis
(21). Moist desquamation occurs when clonogenic cells in
the basal layer are destroyed and thus cannot replace the
damaged tissue. Consequently, the epidermis becomes
damaged (22), and inflammation occurs throughout the
complete treatment period, healing only weeks after the end
of the radiation therapy regimen. Acute skin reactions,
which cause itchiness and pain, can be severe and can thus
become dose-limiting reactions (20).
The aim of the present study was to compare the side
effects of a homogeneous irradiation technique and a
minibeam proton irradiation technique in an in vivo animal
model at clinically relevant beam dimensions and distances.
The present study provides important information toward
implementation of this novel concept into clinical radiation
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Fig. 4. Histologic findings of untreated (control group) ears and ears irradiated with homogeneous field (HF) and mini-
beams (MB) examined 15, 25, 36, and 90 days after irradiation (hematoxylin-eosin stain). No changes were found in the
histologic features of the MB-irradiated ears. In contrast, HF irradiation led to a loss of sebaceous glands (from day 15),
enlargement of the epidermis, inflammation, and fibrosis. The displayed sections of the MB-irradiated ears were not
necessarily through the irradiated spots. Note, ears were necessarily from different mice.
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of this novel irradiation mode on the immune system,
vasculature, and complete metabolism of a whole organism.
The ear of adult BALB/c mice has a layer of skin tissue on
each side of the cartilage (23), allowing examination of
irradiation-induced reactions on both sides simultaneously.
Homogeneous irradiation with 60 Gy induced an up to
fourfold increase in the ear thickness, and a high degree of
edema in both skin layers was found on the histologic
sections. However, no swelling could be detected at any
point after minibeam irradiation at the same mean dose.
Furthermore, no erythema, desquamation, or hair loss was
visible in the mice irradiated with the proton minibeams. In
contrast, those that received homogeneous proton irradia-
tion developed all 3 side effects.
Histologic analysis also identified the loss of the
sebaceous glands, inflammation, and fibrosis and signifi-
cant enlargement of the epidermis only in the
homogeneously irradiated tissue. In contrast, minibeam
irradiation did not induce any significant changes in themorphology compared with the corresponding control
group. A loss of sebaceous glands translates into loss of
sebaceous secretion and a decrease in surface lipid levels
and leads to a deterioration of the skin milieu. This can
manifest itself in the form of dry and sensitive skin in the
irradiated area (24).
An analysis of all endpoints showed that the acute side
effects of proton minibeam radiation therapy at an average
60-Gy dose in BALB/c mouse ears only occurred with
homogeneous x-ray doses of <10 Gy. These findings indi-
cate a dose reduction factor >6. This result can either be
directly translated into a reduction of side effects compared
with broad beam irradiation at the same dose (required to
control the tumor) or be used to enhance the dose within the
tumor for radioresistant cancer types, maintaining the inci-
dence and severity of normal tissue damage at a tolerable
level. Furthermore, proton minibeam irradiation would
allow for hypofractionation during radiation therapy,
because normal tissue damage would not be the main lim-
itation. However, in all cases, tumor control must be ensured
Volume 95  Number 1  2016 Proton minibeams in a mouse ear model 241by a homogeneous dose distribution in the target volume
using appropriate minibeam dimensions and distances. The
maximum possible beam-to-beam distance depends on the
tumor depth, with deeper lying tumors allowing for larger
interbeam distances. All minibeams must widen sufficiently
when approaching the tumor to form a homogeneous dose
distribution in the target volume. Thus, protons reaching the
distal edge of the target volume must have already spread
sufficiently at the proximal edge to ensure a homogeneous
dose distribution throughout the whole target volume.
Similar approaches using minibeams for heavy ion therapy
might also be beneficial; however, the distance, and thus the
size, of the minibeams would have to be reduced compared
with those of protons, owing to the smaller lateral spread of
heavier ions. However, the technical realization of submil-
limeter ion beams remains to be elucidated.
Conclusions
The results from our animal study have clearly demon-
strated that proton minibeam irradiation reduces the inci-
dence of acute side effects compared with conventional
broad beam irradiation in a mouse ear model and could
therefore become an option in clinical proton therapy in the
future.
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